EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition

Donald H Maurice iD

The FEBS Journal · 2025-07 · 292 (13) · 3356-3359

DOI: 10.1111/febs.70059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 07.03.2025. Verfasst von Donald H Maurice. Beteiligte Einrichtung: Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 4, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Institute of Circulatory and Respiratory Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although phosphodiesterase 4 (PDE4) inhibitors have reached the clinic, their lack of selectivity for PDE4 enzyme isoforms leads to documented side effects. Building in enzyme selectivity has proved difficult because all PDE4 enzymes share highly conserved catalytic domains. The report by Sin et al. describes a novel approach in which a potent PDE4 proteolysis targeting chimera (PROTAC) selectively promotes the degradation of a small subset of PDE4 isoforms ( i.e., “short forms”) and impacts inflammatory events regulated by these enzymes. This approach offers unparalleled selectivity, potency, and could represent the dawn of a new pharmacology for selective regulation of cyclic AMP (cAMP) signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 4Phosphodiesterase 4 InhibitorsHumansCyclic AMPProteolysisIsoenzymesAnimalsSignal Transduction

Stichwörter der Autor:innen

PDE4PROTACcAMP‐signalingphosphodiesterases

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 4Phosphodiesterase 4 InhibitorsCyclic AMPIsoenzymes

Autor:innen und Institutionen

  • Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada.

ORCID-Profile: Donald H Maurice

Förderung

  • CIHR
  • Institute of Circulatory and Respiratory Health

Zitieren

APA

Maurice, D. H. (2025). A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition. The FEBS Journal, 292(13), 3356-3359. https://doi.org/10.1111/febs.70059

Vancouver

Maurice DH. A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition. The FEBS Journal. 2025;292(13):3356-3359. doi:10.1111/febs.70059

BibTeX
@article{Maurice2025,
  author = {Maurice, Donald H},
  title = {A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition},
  journal = {The FEBS Journal},
  year = {2025},
  volume = {292},
  number = {13},
  pages = {3356--3359},
  doi = {10.1111/febs.70059}
}
Kostenlos starten →